NCT07279402 TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
| NCT ID | NCT07279402 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Antalya Training and Research Hospital |
| Condition | NSCLC Stage IV |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-09-15 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2025-09-15 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent form. * Diagnosis of stage IV non-small cell lung cancer. * Male or female patients aged 18 years or older. * Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye. * Patients who have received up to 3 cycles of atezolizumab at the screening visit. Exclusion Criteria: * Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication. * Known or suspected hypersensitivity to atezolizumab. * Pregnant or breastfeeding women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07279402 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC Stage IV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07279402 currently recruiting?
Yes, NCT07279402 is actively recruiting participants. Contact the research team at derya.kivraksalim@sbu.edu.tr for enrollment information.
Where is the NCT07279402 trial being conducted?
This trial is being conducted at Adana, Turkey (Türkiye), Afyonkarahisar, Turkey (Türkiye), Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 11 additional locations.
Who is sponsoring the NCT07279402 clinical trial?
NCT07279402 is sponsored by Antalya Training and Research Hospital. The trial plans to enroll 150 participants.